

**IN THE SPECIFICATION:**

Please amend the specification, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents as follows:

Page 1, line 5, please amend the paragraph thereat as follows:

This is a divisional application of U.S. Application Serial No. 09/963,064, filed January 25, 2001, which claims priority to This application claims priority to U.S. Provisional Patent Application No. 60/235,671, filed September 26, 2000, and U.S. Provisional Patent Application Serial No. 60/282,354, filed April 6, 2001.

Page 32, line 19, please amend the chart thereat as follows:

CLONE	V3 LOOP SEQUENCE	CORECEPTOR
AF2P12-1	CIRPNNNTRTSIRIGPGQAFYATGNIIGDIRQAYC	CCR5 (SEQ ID NO.1)
AF2P12-2	CIRPNNNTRTSIRIGPGQAFYATGNIIGGIRQAYC	CCR5 (SEQ ID NO.26)
AF2P12-3	CIRPNNNTRTSIRIGPGQAFYATGNIIGDIRQAYC	CCR5 (SEQ ID NO.1)
AF2P12-4	CIRPNNNTRTSIRIGPGQAFYATGNIIGDIRQAYC	CCR5 (SEQ ID NO.1)
AF2P12-6	CIRPNNNTRTSIRIGPGQAFYATGNIIGDIRQAYC	CCR5 (SEQ ID NO.1)
AF2P12-8	CIRPNNNTRTSIRIGPGQAFYATGNIIGDIRQAYC	CCR5 (SEQ ID NO.1)
AF2P12-9	CIRPNNNTRTSIRIGPGQAFYATGNIIGDIRQAYC	CCR5 (SEQ ID NO.1)
AF2P12-10	CIRPNNNTRTSIRIGPRQAFYATGNIIGDIRQAYC	CXCR4 (SEQ ID NO.2)
AF2P12-11	CIRPNNNTRTSIRIGPGQAFYATGNIIGDIRQAYC	CCR5 (SEQ ID NO.3)
AF2P12-12	CIRPNNNTRTSIRIGPGQAFYATGNIIGDIRQAYC	CCR5 (SEQ ID NO.1)
AF3P-2	.....RKSVHIGPGQAFYATGDIIGNIRKAHC	negative (SEQ ID NO.4)
AF3P-4	CTRPNNNTRKSVHIGPGQAFYATGDIIGNIRKAHC	CCR5 (SEQ ID NO.5)
AF3P-5	CTRPNNNTRKSVHIGPGQAFYATGDIIGNIRKAHC	CCR5 (SEQ ID NO.5)
AF3P-6	CTRPNNNTRKSVHIGPGQAFYATGDIIGNIRKAHC	CCR5 (SEQ ID NO.6)
AF3P-7	CTRPNNNTRKSVHIGPGQAFYATGDIIGNIRKAHC	CCR5 (SEQ ID NO.5)
AF3P-8	CTRPNNNTRKSVHIGPGQAFYATGDIIGNIRKAHC	CCR5 (SEQ ID NO.5)
AF3P-9	CTRPNNNTRKSVHIGLQAFYATGDIIGNIRKAHC	CCR5 (SEQ ID NO.27)
AF3P-10	CTRPNNNTRKSVHIGPGQAFYATGDIIGNIRKAHC	CCR5 (SEQ ID NO.5)
AF3P-11	CTRPNNNTRKSVHIGPGQAFYATGDILGNIRKAHC	CCR5 (SEQ ID NO.28)
AF3P-12	CTRPNNNTRKSVHIGPGQAFYATGDIIGNMRKAHC	CCR5 (SEQ ID NO.7)
AF5P-5	CTRPNNNTRKSVHIGPGQAFYATGDIIGDIRQAYC	CCR5 (SEQ ID NO.29)
AF5P-6	CTRPNNNTKKSIVHIGPGQAFYATGDIIGDIRQAYC	CCR5 (SEQ ID NO.30)
AF5P-8	CTRPNNNTRKSVHIGPGQAFYATGDIIGDIRQAYC	CCR5 (SEQ ID NO.29)
AF6P-1	CTRPINNRRKSIHMGPGQAFYGT.DDIIGDIRKARC	CCR5 (SEQ ID NO.8)
AF6P-3	CTRPINNRRKSIHMGPGQAFYGT.DDIIGDIRKARC	CCR5 (SEQ ID NO.8)
AF6P-7	CTRPSNNRRKSIHKGDQDKHSMEHDDVIGDIRKARC	negative (SEQ ID NO.9)
AF6P-9	CTRPINNRRKSIHMGPGQAFYGT.DDIIGDIRKARC	CCR5 (SEQ ID NO.8)
AF6P-10	CTRPINNRRKSIHIGPGQAFYGT.DDIIGDIRQAHC	CCR5 (SEQ ID NO.32)
AF6P-11	CTRPSNNRRKSIHMGPGQAFYGT.DDIIGGIRKARC	CCR5 (SEQ ID NO.33)
AF6P-12	CTRPSNNRRKSIHMGPGQAFYGT.DDIIGDIRKARC	CCR5 (SEQ ID NO.34)

AF7P-9	CIRPNNNTRQSVHIGPGQALYTTTEIIGDIRKAHC	CCR5	(SEQ ID NO. 11)
AF7P-12	CIRPNNNTRQSVHIGPGQALYTTTEIIGDIRKAHC	CCR5	(SEQ ID NO. 11)
AF9P2-3	CTRPNNNTITSIRIGPGQAFYATGSIIGNIRQAHC	CCR5	(SEQ ID NO. 12)
AF9P2-4	CTRPNNNTITSIRIGPGQAFYATGSIIGNTRQAHC	CCR5	(SEQ ID NO. 13)
AF9P2-7	CTRPNNNTITSIRIGPGQAFYATGSIIGNIRQAHC	CCR5	(SEQ ID NO. 12)
AF9P2-9	CTRPNNNTITSIRIGPGQAFYATGSIIGNIRQAHC	CCR5	(SEQ ID NO. 12)
AF9P2-10	CTRPNNNTITSIRIGPGQAFYATGSIIGNIRQAHC	CCR5	(SEQ ID NO. 12)
AF9P2-11	CTRPNNNTITSIRIGPGQAFYATGSIIGNIRQAHC	CCR5	(SEQ ID NO. 12)
AF9P2-12	CTRPNNNTITSIRIGPGQAFYATGSIIGNIRQAHC	CCR5	(SEQ ID NO. 12)
AF10P97-2	CTRPNDNIRKSVHIGPGQAFYATGDIIGDIRRAHC	CCR5	(SEQ ID NO. 14)
AF10P97-4	CTRPNDNIRKRVHIGPGQAFYATGDVIGDIRRAHC	CXCR4	(SEQ ID NO. 31)
AF10P97-6	CTRPNDNIRKSVHIGPGQAFYATGDIIGDIRRAHC	CCR5	(SEQ ID NO. 14)
AF10P97-11	CTRPNDNIRKSVHIGPGQAFYATGDIIGDIRRAHC	CCR5	(SEQ ID NO. 14)

Page 37, line 12, please amend the paragraph thereat as follows:

8. Sequence analysis:

- a) The DNA sequence of the env V3 loop was determined.
- b) Protein translation of the V3 loop was determined.
- c) CCR5 or CXCR4 predictions were based on the scheme outlined

below:

	268	
	290	
Clade B		
consensus:	N N T R K - I - I G P G - A - - - T G - I I G (SEQ ID NOS: 22-25)	
R5 strain if	1.	G/S at residue 273 and D/E at residue 287
	2.	K,H,R at residue 275 and D/E at residue 287
	3.	Not K,H,R at residue 275 but D/E/K/H/R at residue 287
X4 strain if:	1.	K,H,R at residue 275 and K/H/R at residue 287

- d) The lambda value for the patient was calculated as:

$$\lambda = (\# \text{ of R5 clones}) / (\text{total } \# \text{ of clones})$$

Page 8, line 4, (i.e., before the Detailed Description, please insert):

The file of this patent contains at least one drawing executed in color. Copies of this patent with color drawing(s) will be provided by the Patent and Trademark Office upon request and payment of the necessary fee.

After the last page of the specification (page 37), and before the first page of claims, kindly replace the previously filed Sequence Listing with the enclosed pages entitled --Sequence Listing--.